Macromolecular therapeutics: Development and delivery engineering

Gang Zhao, Xin Wei, Dong Wang

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Macromolecular therapeutics have been developed to improve the efficacy and safety profile of varied therapeutic agents for different disease more than 50 years ago. N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers as a drug delivery platform have been extensively studied and applied in the clinical trials. Recently, the application of HPMA copolymers in the treatment of non-cancerous diseases such like infectious diseases and musculoskeletal diseases has also been explored widely. In this chapter, different formulations of macromolecular therapeutics will be discussed. The design principles illustrated in the development of HPMA copolymer drug conjugates are also valid for other hydrophilic polymers, and they will be the principal focus of our discussion. Active targeting of HPMA copolymers based on targeting moieties and passively targeting HPMA copolymers based on the Enhanced Permeability and Retention (EPR) effect for cancer disease and Extravasation through Leaky Vasculature and subsequent Inflammatory cell-mediated Sequestration (ELVIS) mechanism for inflammation disease will also be discussed in this chapter.

Original languageEnglish (US)
Title of host publicationNeuroimmune Pharmacology
PublisherSpringer International Publishing
Pages869-883
Number of pages15
ISBN (Electronic)9783319440224
ISBN (Print)9783319440200
DOIs
StatePublished - Jan 1 2016

Fingerprint

Musculoskeletal Diseases
Therapeutics
Pharmaceutical Preparations
Communicable Diseases
Permeability
Polymers
N-(2-hydroxypropyl)methacrylamide
Clinical Trials
Inflammation
Safety
Neoplasms
glutamyl-leucyl-valyl-isoleucyl-serine

Keywords

  • Cancer therapy
  • Central nervous system (CNS)
  • Hydroxypropyl methacrylamide HPMA copolymers
  • Targeting

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Zhao, G., Wei, X., & Wang, D. (2016). Macromolecular therapeutics: Development and delivery engineering. In Neuroimmune Pharmacology (pp. 869-883). Springer International Publishing. https://doi.org/10.1007/978-3-319-44022-4_51

Macromolecular therapeutics : Development and delivery engineering. / Zhao, Gang; Wei, Xin; Wang, Dong.

Neuroimmune Pharmacology. Springer International Publishing, 2016. p. 869-883.

Research output: Chapter in Book/Report/Conference proceedingChapter

Zhao, G, Wei, X & Wang, D 2016, Macromolecular therapeutics: Development and delivery engineering. in Neuroimmune Pharmacology. Springer International Publishing, pp. 869-883. https://doi.org/10.1007/978-3-319-44022-4_51
Zhao G, Wei X, Wang D. Macromolecular therapeutics: Development and delivery engineering. In Neuroimmune Pharmacology. Springer International Publishing. 2016. p. 869-883 https://doi.org/10.1007/978-3-319-44022-4_51
Zhao, Gang ; Wei, Xin ; Wang, Dong. / Macromolecular therapeutics : Development and delivery engineering. Neuroimmune Pharmacology. Springer International Publishing, 2016. pp. 869-883
@inbook{394e845c43bc452d8f66fc26b60b72ae,
title = "Macromolecular therapeutics: Development and delivery engineering",
abstract = "Macromolecular therapeutics have been developed to improve the efficacy and safety profile of varied therapeutic agents for different disease more than 50 years ago. N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers as a drug delivery platform have been extensively studied and applied in the clinical trials. Recently, the application of HPMA copolymers in the treatment of non-cancerous diseases such like infectious diseases and musculoskeletal diseases has also been explored widely. In this chapter, different formulations of macromolecular therapeutics will be discussed. The design principles illustrated in the development of HPMA copolymer drug conjugates are also valid for other hydrophilic polymers, and they will be the principal focus of our discussion. Active targeting of HPMA copolymers based on targeting moieties and passively targeting HPMA copolymers based on the Enhanced Permeability and Retention (EPR) effect for cancer disease and Extravasation through Leaky Vasculature and subsequent Inflammatory cell-mediated Sequestration (ELVIS) mechanism for inflammation disease will also be discussed in this chapter.",
keywords = "Cancer therapy, Central nervous system (CNS), Hydroxypropyl methacrylamide HPMA copolymers, Targeting",
author = "Gang Zhao and Xin Wei and Dong Wang",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-3-319-44022-4_51",
language = "English (US)",
isbn = "9783319440200",
pages = "869--883",
booktitle = "Neuroimmune Pharmacology",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Macromolecular therapeutics

T2 - Development and delivery engineering

AU - Zhao, Gang

AU - Wei, Xin

AU - Wang, Dong

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Macromolecular therapeutics have been developed to improve the efficacy and safety profile of varied therapeutic agents for different disease more than 50 years ago. N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers as a drug delivery platform have been extensively studied and applied in the clinical trials. Recently, the application of HPMA copolymers in the treatment of non-cancerous diseases such like infectious diseases and musculoskeletal diseases has also been explored widely. In this chapter, different formulations of macromolecular therapeutics will be discussed. The design principles illustrated in the development of HPMA copolymer drug conjugates are also valid for other hydrophilic polymers, and they will be the principal focus of our discussion. Active targeting of HPMA copolymers based on targeting moieties and passively targeting HPMA copolymers based on the Enhanced Permeability and Retention (EPR) effect for cancer disease and Extravasation through Leaky Vasculature and subsequent Inflammatory cell-mediated Sequestration (ELVIS) mechanism for inflammation disease will also be discussed in this chapter.

AB - Macromolecular therapeutics have been developed to improve the efficacy and safety profile of varied therapeutic agents for different disease more than 50 years ago. N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers as a drug delivery platform have been extensively studied and applied in the clinical trials. Recently, the application of HPMA copolymers in the treatment of non-cancerous diseases such like infectious diseases and musculoskeletal diseases has also been explored widely. In this chapter, different formulations of macromolecular therapeutics will be discussed. The design principles illustrated in the development of HPMA copolymer drug conjugates are also valid for other hydrophilic polymers, and they will be the principal focus of our discussion. Active targeting of HPMA copolymers based on targeting moieties and passively targeting HPMA copolymers based on the Enhanced Permeability and Retention (EPR) effect for cancer disease and Extravasation through Leaky Vasculature and subsequent Inflammatory cell-mediated Sequestration (ELVIS) mechanism for inflammation disease will also be discussed in this chapter.

KW - Cancer therapy

KW - Central nervous system (CNS)

KW - Hydroxypropyl methacrylamide HPMA copolymers

KW - Targeting

UR - http://www.scopus.com/inward/record.url?scp=85045990701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045990701&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-44022-4_51

DO - 10.1007/978-3-319-44022-4_51

M3 - Chapter

AN - SCOPUS:85045990701

SN - 9783319440200

SP - 869

EP - 883

BT - Neuroimmune Pharmacology

PB - Springer International Publishing

ER -